Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
May 21, 2019 08:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to...
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
February 11, 2019 16:05 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for...
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
November 05, 2018 07:00 ET
|
Abeona Therapeutics Inc.
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10...
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
September 12, 2018 08:45 ET
|
Abeona Therapeutics Inc.
Clinical trial for ABO-101 (AAV-NAGLU) marks the 2nd MPS III program in EuropeCompany plans to initiate additional clinical sites in European countries including France, Germany and the United Kingdom...
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
May 11, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Presentations
May 08, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
February 08, 2018 14:00 ET
|
Abeona Therapeutics Inc.
ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS...
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
December 20, 2017 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
November 09, 2017 08:45 ET
|
Abeona Therapeutics Inc.
Company Opens European Subsidiary in Spain to Support Global Clinical DevelopmentNine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW...